Market News AIOpen the app

Anteris Technologies Reports Positive 30-Day Outcomes for Medium-Size DurAVR THV in EMBARK Study

TrialRead the original at globenewswire.com
Good for AVR

Anteris reported favorable 30-day valve and safety results in 22 patients, supporting its heart-valve program. The small group and short follow-up limit what these results show.

AVR · Anteris Technologies

AI read · Good for AVR

The AI's read

Better blood-flow measurements and no listed major valve complications give the device encouraging early evidence. Still, results from 22 people after only 30 days cannot show how well it works for larger groups or over time.

Get alerts for AVR

Follow Anteris Technologies (AVR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AVR
Free on the App Store and Google Play, or on the web.